MongoDB Available For Sale Securities Debt Securities Current decreased by 11.4% to $1.30B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 29.4%, from $1.85B to $1.30B. Over 5 years (FY 2021 to FY 2026), Available For Sale Securities Debt Securities Current shows an upward trend with a 19.8% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $527.99M | $653.83M | $1.05B | $1.35B | $1.37B | $1.14B | $787.86M | $1.38B | $1.18B | $1.29B | $1.45B | $1.21B | $1.26B | $973.93M | $1.63B | $1.85B | $1.80B | $1.70B | $1.47B | $1.30B |
| QoQ Change | — | +23.8% | +61.3% | +28.2% | +1.5% | -16.6% | -31.1% | +75.3% | -14.4% | +9.5% | +11.8% | -16.2% | +3.8% | -22.6% | +67.3% | +13.3% | -2.7% | -5.4% | -13.3% | -11.4% |
| YoY Change | — | — | — | — | +159.9% | +75.0% | -25.3% | +2.1% | -13.9% | +13.1% | +83.7% | -12.2% | +6.5% | -24.7% | +12.6% | +52.3% | +42.7% | +74.4% | -9.7% | -29.4% |